Your browser doesn't support javascript.
loading
Repurposing Antihypertensive and Statin Medications for Spinal Pain: A Mendelian Randomization Study.
Suri, Pradeep; Elgaeva, Elizaveta E; Williams, Frances M K; Freidin, Maxim B; Verzun, Dmitrii A; Tsepilov, Yakov A.
Afiliação
  • Suri P; Division of Rehabilitation Care Services, VA Puget Sound Health Care System, Seattle, WA.
  • Elgaeva EE; Seattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, WA.
  • Williams FMK; Clinical Learning, Evidence, and Research (CLEAR) Center, University of Washington, Seattle, WA.
  • Freidin MB; Department of Rehabilitation Medicine, University of Washington, Seattle, WA.
  • Verzun DA; Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia.
  • Tsepilov YA; Laboratory of Recombination and Segregation Analysis, Institute of Cytology and Genetics, Novosibirsk, Russia.
Spine (Phila Pa 1976) ; 48(22): 1568-1574, 2023 Nov 15.
Article em En | MEDLINE | ID: mdl-37539717
ABSTRACT
STUDY

DESIGN:

Mendelian randomization (MR) study.

OBJECTIVE:

To examine whether antihypertensive medications (beta-blockers, calcium channel blockers, and angiotensin-converting enzyme inhibitors) and statins can be repurposed to prevent or treat spinal pain (back or neck pain). SUMMARY OF BACKGROUND DATA Observational studies and a recent MR study have found associations between elevated blood pressure and a greater risk of back pain. Observational studies have found associations between hyperlipidemia and statin use and greater risk of back pain. No prior MR studies have examined the effects of antihypertensives or statins on spinal pain. MATERIALS AND

METHODS:

This was a two-sample MR study using publicly available summary statistics from large-scale genome-wide association studies (GWAS). Sample sizes in exposure GWASs were n=757,601 (systolic blood pressure) and n=173,082 (low-density lipoprotein cholesterol), and n=1,028,947 for the outcome GWAS of spinal pain defined as health care seeking for any spinal pain-related diagnosis. Genes and cis-acting variants were identified as proxies for the drug targets of interest. MR analyses used inverse-variance weighted meta-analysis. The threshold for statistical significance after correction for multiple testing was P <0.0125.

RESULTS:

No statistically significant associations of these medications with spinal pain were found. However, findings were suggestive of a protective effect of beta-blockers on spinal pain risk (odds ratio [OR] 0.84, 95% confidence interval [CI] 0.72-0.98; P =0.03), and calcium channel blockers on greater spinal pain risk (OR 1.12, 95% CI 1.02-1.24; P =0.02).

CONCLUSIONS:

A protective effect of beta-blockers on spinal pain was suggested in the current study, consistent with findings from observational studies of various other pain phenotypes. The detrimental effect of calcium channel blockers on spinal pain suggested in the current study must be interpreted in the context of conflicting directions of effect on nonspinal pain phenotypes in other observational studies.This Mendelian randomization study examined whether antihypertensive medications (beta-blockers, calcium channel blockers, and angiotensin-converting enzyme inhibitors) and statins can be repurposed to prevent or treat spinal.This was a two-sample MR study using publicly available summary statistics from large-scale genome-wide association studies ranging size from 173,082 to 1,028,947 adults.While no statistically significant associations were found, a protective effect of beta-blockers on spinal pain was suggested (odds ratio [OR] 0.84, 95% confidence interval [CI] 0.72 to 0.98; p= 0.03), as was a detrimental effect of calcium channel blockers on spinal pain (OR 1.12, 95% CI 1.02 to 1.24; p= 0.02).
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Anti-Hipertensivos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Anti-Hipertensivos Idioma: En Ano de publicação: 2023 Tipo de documento: Article